Calling for 150 most important questions in cancer research and clinical oncology

Chinese Journal of Cancer serves as an important platform to report the international efforts in the war against cancer. We are keen to hear your ideas on the trend and novel ideas in cancer treatments.The 150 ideas will be published in a special article in December. Find out more.

Articles

View all articles

View all articles

Aims and scope

Chinese Journal of Cancer (CJC) is an open access, peer-reviewed online journal that encompasses basic, clinical, and translational cancer research. CJC welcomes submissions concerning clinical trials, epidemiology, molecular and cellular biology, and genetics.

Society Affiliations

Chinese Journal of Cancer is affiliated to the Chinese Anti-Cancer Association and the US Chinese Anti-Cancer Association.

                      

The journal is fully sponsored by Sun Yat-sen University Cancer Center, so authors do not need to pay an article-processing charge.

Archival content

To browse articles published in the journal prior to March 2015, please visit the Sun Yat-sen University Cancer Center website.

Special series on tumor angiogenesis

Forming efficient vasculature network, also known as tumor angiogenesis, is a critical hallmark in tumor development. Explorations on its underlying molecular mechanisms have resulted in several novel anti-cancer drugs. However, the modest survival benefits from anti-angiogenic therapy have forced us to revisit our understanding on tumor angiogenesis. In this special issue, world-leading experts have contributed their critical thoughts to reveal alternative tumor angiogenesis approaches and potential treatment targets.

Read thematic series >

Special series on lung cancer

Lung cancer accounts for approximately 21% of worldwide cancer deaths and a staggering 1.6 million new cases are diagnosed every year. In China, lung cancer has become a particularly challenging disease because of air pollution and smoking. This thematic series discusses the proper use of targeted agents in treating lung cancer, reviews the application of biomarkers in clinical management and drug development, and analyzes the unique challenges in developing novel drugs for lung cancer in China.

Read thematic series >

Advertisement